VALIRX PLC

Pre-Annual General Meeting Information • Dec 6, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4819Y

ValiRx PLC

06 December 2017

VALIRX PLC

("ValiRx" or "the Company")

SHAREHOLDER CIRCULAR AND NOTICE OF GENERAL MEETING

London, UK, 6 December 2017: ValiRx Plc (AIM: VAL), a clinical stage biotechnology announces that it has recently published and posted to shareholders a circular and notice convening a General Meeting of ValiRx Plc to be held at the offices of DAC Beachcroft LLP at 100 Fetter Lane, London EC4A 1BN at 9:00 a.m. on 21 December 2017.

The directors will propose at the General Meeting shareholder resolutions seeking shareholder authority to allot shares and the dis-application of pre-emptive rights.

A copy of the Circular will be available on the Company's website shortly: www.valirx.com

- ENDS -

For more information, please contact:

ValiRx plc	Tel: +44 (0) 20 3008 4416
Dr Satu Vainikka, Chief Executive Tarquin Edwards, Investor Relations	www.valirx.com Tel: +44 (0) 7879 458 364 tarquin.edwards@valirx.com
Cairn Financial Advisers LLP (Nominated Adviser)	Tel: +44 (0) 20 7213 0880
Liam Murray / Jo Turner
Beaufort Securities Limited (Broker)	Tel: +44 (0) 20 7382 8300
Jon Belliss

Notes for Editors

About ValiRx Plc

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention. 

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field. 

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College.  

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients. 

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCTABRTMBJMBJR